

Chair: Charlotte Skitterall, Chief Pharmacist, MFT
Vice Chair: Claire Vaughan, Head of Medicines Optimisation, Salford CCG
Enquiries: Monica Mason, Head of Prescribing Support, RDTG
 (tel : 0191 213 7855, email: rdtc.rxsupp@nuth.nhs.uk)

HIGH COST DRUGS SUBGROUP

Wednesday 26th September 2018, 10am until 12 noon.
Community Room 1, Pendleton Gateway, Salford

Minutes

1. General Business	
1.1	<p>Welcome and apologies (See register in appendix 1) Apologies as per register were noted.</p>
1.2	<p>Conflicts of Interest AM declared that he had attended an advisory board for Amgen in July 2018, it was agreed that he would leave the room for the discussions concerning adalimumab biosimilar.</p>
1.3	<p>1. Minutes The draft minutes from the August meeting were agreed as accurate Action: Publish on GMMMG website following CSB</p>
1.4	<p>Actions and Matters arising</p> <p>Biosimilar assurance reporting: it was agreed that GMSS should contact Chief Pharmacists and Trust HCD pharmacists as well as CCG MO pharmacists to obtain the information necessary for the compilation of this report. A template to aid data collection should be distributed, and the report should interpret the data presented to aid assurance discussions locally, to CSB and the JCB. Action: AM to develop and distribute template as above and return a quarterly assurance report to HCDSG, with the first report returning to the October HCDSG meeting and then the December CSB meeting</p> <p>High Cost Drug Reporting: HCDSG were updated on discussions from the BI working group meeting the previous week, and the progress made by GMSS on the development of a HCD dashboard. Action: GMSS to produce a quarterly report, with stage one (presentation of the data available) returning to the October meeting.</p>

	<p>Managed entry of Dupilumab: A report on the steps taken to manage the entry of dupilumab across the GM economy, based on the information previously communicated to HCDSG had been drafted for CSB submission. Assurance reporting of dupilumab prescribing (i.e. to show prescribing in line with the agreed criteria and response rate) would be monitored across GM using Blueteq, and would return to HCDSG monthly from October and quarterly thereafter, with communication to CSB as appropriate.</p> <p>Action: HCDSG statement on managed entry of dupilumab to be submitted to CSB in October, thereafter quarterly as agreed.</p> <p>GMMMG Biologics Pathway for psoriasis: It was noted that two meetings had been arranged to undertake a full review of this pathway. As per GMMMG process a scoping document would need to be submitted for HCDSG consideration.</p> <p>Action: Scoping template for the full review of this pathway to be considered at the October HCDSG meeting</p> <p>“Mabs” for migraine: A brief update on the current situation was considered in light of the delayed NICE consideration date.</p> <p>Action: HCDSG to review these agents at the October meeting and develop criteria to manage their entry across GM prior to a NICE position being published.</p>
--	--

2. Medicines Optimisation

2.1	<p>Adalimumab biosimilar procurement update</p> <p>HCDSG received an update on the proposed national tendering model for adalimumab and the upcoming biosimilar products. There was discussion around how this may affect the GMMMG directed work being undertaken across GM, and whether this could alter the anticipated savings to the GM health economy.</p> <p>It was agreed that a briefing paper should be drafted outlining the possible outcomes if this revised tendering model is implemented over the more typical model. Communication to finance and commissioning teams should also be drafted and submitted for CSB approval, although it was recognised that as this tender process is in draft form there are still uncertainties as to the possible outcomes.</p>
2.2	<p>Progress report on GM biosimilar adalimumab project – September 2018</p> <p>It was noted that the planned adalimumab telecom had been substituted for an email dialogue, and aspects of the project had been progressed in this manner. However it was now acknowledged that the proposed changes to the adalimumab biosimilar tendering model may affect the work currently being undertaken through this project. It was agreed that this project would continue to focus on the operational aspects of adalimumab biosimilar delivery, and that there was still value in hosting the adalimumab biosimilar roadshow for pharmacist attendees.</p> <p>Action: HCDSG to draft a communication to finance and commissioning teams concerning the potential risks to the GM adalimumab biosimilar project objectives.</p> <p>Adalimumab roadshow to be delivered as planned but for pharmacist attendees only</p>

<p>2.3</p>	<p>Outcome of the “Avastin” judicial review in the NE of England</p> <p>The group noted the outcome of the JR, there was some short discussion around the possible implications of this decision and an acknowledgment that further detailed discussion on many associated issues would need to be undertaken, if GM wished to consider this item further. In particular HCDSG commented that the membership of any GM working group tasked with consideration of this topic would need to reflect the issues posed i.e. the fragility of NHS aseptic production units and the aspects of production/procurement of a suitable product. It was expected that the MHRA would issue a response to this judgement and also that an appeal against this decision would be lodged, in which case it would be prudent to watch and wait, and that a holding statement should be drafted to this affect.</p> <p>Action: MM to draft a letter/holding statement from HCDSG to GM finance and commissioning teams via CSB. HCDSG to await an update from CSB with regards the next steps for GM in this area.</p>
<p>2.4</p>	<p>Commissioner requirements for format of High Cost Drugs recharging information</p> <p>It was noted that a gap analysis of the data required was to be undertaken by GMSS, and that this information would be shared with GM commissioners, but that there was no action for HCDSG at this stage.</p>
<p>3. Horizon scanning and work planning</p>	
<p>3.1</p>	<p>RDTc MHSd (includes MHRA DSU links) (Sept 2018) and work plan</p> <p>As Prescribing Outlook had not published, it was agreed that AM would progress the annual horizon scanning round using relevant information from the 2017 version, plus additional information from RDTc monthly horizon scanning documents and return a draft to the October meeting.</p> <p>Action: First draft HS paper to return to the October HCDSG meeting</p>
<p>4. Communication from other groups</p>	
	<ul style="list-style-type: none"> • GM HCD optimisation network • Medicines Optimisation Clinical Reference Group • HIM • Chief Pharmacists • RMOC <p>There was no further updates other than that covered above.</p>
<p>5. AOB</p>	

Nil

Date of next meeting: Wednesday 31st October 2018, Swinton Room, St James House, Salford

Attendee	F	M	A	M	J	J	A	S	O	N	J
Charlotte Skitterall Chief Pharmacist, MFT		✓	✓	✓	✓		✓	✓			
Danielle Timoney Lead Pharmacist, Med Man, FT		A	✓	✓	✓		✓	A			
Steve Simpson Chief Pharmacist, Bolton Trust		✓	✓	A	✓		✓	A			
Paul Buckley Chief Pharmacist, Stockport Trust		A	A	A	✓		✓	A			
Darren Staniforth HCD Pharmacist, MFT		A	✓	✓	✓		✓	✓			
Selwa Elrouby or Andrea Marrosu HCD pharmacist or MI pharmacist, SRFT		✓ SE	✓ AM	✓ A M	✓ A M		A	✓ AM			
Robert Eley Specialist Pharmacist, PAT		✓	✓	✓	✓		✓	✓			
Claire Vaughan Head of MO, Salford CCG		✓	✓	✓	✓		✓	✓			
Jeanette Tilstone Head of MO, Bury CCG		A	✓	✓	✓		✓	A			
Susan McKernan Senior MO Adviser, North Manchester CCG		A ✓ KL	✓	✓	✓		✓	✓			
Jole Hannan CCG Interface Pharmacist, Bolton CCG		A	A	✓	A		✓	A			
David Dolman Deputy Chief Finance Officer, Stockport CCG		A	A	A	✓		A	✓			
Glenn Harley NW Procurement lead		✓	A	✓	✓		A	✓			
Connie Chen GP, MHCC		A	✓	A	A		✓	A			
Consultant rheumatologist (Therese Brammah, Sahena Haque, Louise Mercer, Surabhi Wig (Bolton) or Charlie Filer)		✓ SH	✓ SW	✓ CF	✓ CF		A				
Sarah Jacobs Head of MO, GM Shared Service		✓	✓	✓	✓		✓	✓			
Andrew Martin Strategic MO Pharmacist, GM Shared Service		✓	✓	✓	✓		✓	✓			
Anna Pracz MO pharmacist, GM Shared Service		✓	✓	✓	✓		✓	✓			
Brian Galea Systems Administrator, GM Shared Service		A	A	A	A		✓	A			
Monica Mason Head of Prescribing Support, RDTC		✓	✓	✓	✓		✓	✓			